Taking advantage of one of the most important conferences for the rabbit sector, the World Rabbit Congress, HIPRA presented 6 studies focused on the efficacy against the most virulent strains of RHDV2 and the benefits obtained after the application of YURVAC® RHD.

Sandra Gascon Torrens (Global Product Manager, HIPRA) and Massimiliano Baratelli (R&D Post Marketing Studies Business Partner) were there presenting the studies and answering questions from the attendees, who showed great interest in the results obtained. 

The main results from these studies concluded that YURVAC® RHD: 

• Is effective against the highly virulent strain of RHDV2, as well as the classic strain. 
• Can be administered to pregnant and lactating does without affecting reproductive parameters. 
• An extensive field study, including almost 6,000 rabbits, allowed the assessment of the safety of the vaccine and the serological response in animals vaccinated in the presence of maternal immunity. 
• Is effective in protecting rabbits against different strains of rabbit haemorrhagic disease. 
• Shows a better performance in controlling outbreaks of rabbit haemorrhagic disease.
• Has demonstrated protection in kits from vaccinated does, offering maternal immunity for up to at least 30 days of life.

In addition to the studies on YURVAC® RHD, a seventh poster on myxomatosis was also presented, demonstrating that recurrent vaccination of does with MIXOHIPRA®-H does not have a negative impact on their antibody response.

Through its research and participation in this event, HIPRA demonstrates its commitment to the rabbit sector.